Methotrexate and liver fibrosis in people with psoriasis: A systematic review of observational studies

British Journal of Dermatology

Volumn 171, Issue 1, 2014, Pages 17-29

  Maybury, C M ^a   Jabbar Lopez, Z K ^b   Wong, T ^c   Dhillon, A P ^d   Barker, J N ^a   Smith, C H ^a,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; FOLIC ACID; METHOTREXATE; PLACEBO; DERMATOLOGICAL AGENT;

ALCOHOL CONSUMPTION; ATTRIBUTABLE RISK; CHECKLIST; CLINICAL ASSESSMENT; COCHRANE LIBRARY; COMORBIDITY; DATA EXTRACTION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EMBASE; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MEDLINE; META ANALYSIS; NONALCOHOLIC FATTY LIVER; OBESITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PSORIASIS; PUBLISHING; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SELECTION BIAS; SYSTEMATIC REVIEW; VITAMIN SUPPLEMENTATION; CHEMICALLY INDUCED; PROGNOSIS;

COMORBIDITY; DERMATOLOGIC AGENTS; HUMANS; LIVER CIRRHOSIS; METHOTREXATE; OBSERVATIONAL STUDIES AS TOPIC; PROGNOSIS; PSORIASIS; PUBLICATION BIAS; SELECTION BIAS;

EID: 84904964178     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12941     Document Type: Review

References (32)

1. Menter A, Korman NJ, Elmets CA, et al,. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009; 61: 451-85.
2. Pathirana D, Ormerod AD, Saiag P, et al,. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl. 2): 1-70.
3. Samarasekera E, Sawyer L, Parnham J, et al,. Assessment and management of psoriasis: of NICE guidance. BMJ 2012; 345: e6712.
4. Dahl MG, Gregory MM, Scheuer PJ,. Liver damage due to methotrexate in patients with psoriasis. BMJ 1971; 1: 625-30.
5. Langan SM, Seminara NM, Shin DB, et al,. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol 2012; 132: 556-62.
6. Armstrong AW, Harskamp CT, Armstrong EJ,. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol 2013; 149: 84-91.
7. Armstrong AW, Harskamp CT, Armstrong EJ,. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol 2013; 68: 654-62.
8. Ma C, Harskamp CT, Armstrong EJ, et al,. The association between psoriasis and dyslipidaemia: a systematic review. Br J Dermatol 2013; 168: 486-95.
9. Gisondi P, Targher G, Zoppini G, et al,. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 758-64.
10. Miele L, Vallone S, Cefalo C, et al,. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 778-86.
11. National Institute for Health and Care Excellence. CG153. Psoriasis: the Assessment and Management of Psoriasis. London: NICE; October 2012. Available at: http://guidance.nice.org.uk/CG153 (last accessed 16 April 2014).
12. Yeung H, Takeshita J, Mehta NN, et al,. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol 2013; 149: 1173-9.
13. World Gastroenterology Organisation. World Gastroenterology Organisation Global Guidelines: Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. WGO, 2012. Available at: http://www.worldgastroenterology.org/ assets/export/userfiles/2012-NASH%20and%20NAFLD-Final-long.pdf (last accessed 1 April 2014).
14. Wenk KS, Arrington KC, Ehrlich A,. Psoriasis and non-alcoholic fatty liver disease. J Eur Acad Dermatol Venereol 2011; 25: 383-91.
15. Rodenhuis S, Kremer JM, Bertino JR,. Increase of dihydrofolate reductase in peripheral blood lymphocytes of rheumatoid arthritis patients treated with low-dose oral methotrexate. Arthritis Rheum 1987; 30: 369-74.
16. Kremer JM,. Toward a better understanding of methotrexate. Arthritis Rheum 2004; 50: 1370-82.
17. Prey S, Paul C,. Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. Br J Dermatol 2009; 160: 622-8.
18. Al-Dabagh A, Davis SA, Kinney MA, et al,. The effect of folate supplementation on methotrexate efficacy and toxicity in psoriasis patients and folic acid use by dermatologists in the USA. Am J Clin Dermatol 2013; 14: 155-61.
19. Whiting-O'Keefe QE, Fye KH, Sack KD,. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991; 90: 711-16.
20. Montaudie H, Sbidian E, Paul C, et al,. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Eur Acad Dermatol Venereol 2011; 25: 12-18.
21. Rosenberg P, Urwitz H, Johannesson A, et al,. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 2007; 46: 1111-18.
22. Bradford Hill A,. The environment and disease: association or causation? Bull World Health Organ 2005; 83: 796-8.
23. Langman G, Hall PM, Todd G,. Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol 2001; 16: 1395-401.
24. Zachariae H, Heickendorff L, Sogaard H,. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up. Br J Dermatol 2001; 144: 100-3.
25. Malatjalian DA, Ross JB, Williams CN, et al,. Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. Can J Gastroenterol 1996; 10: 369-75.
26. Boffa MJ, Chalmers RJ, Haboubi NY, et al,. Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal. Br J Dermatol 1995; 133: 774-8.
27. Themido R, Loureiro M, Pecegueiro M, et al,. Methotrexate hepatotoxicity in psoriatic patients submitted to long-term therapy. Acta Derm Venereol 1992; 72: 361-4.
28. Nyfors A, Poulsen H,. Liver biopsies from psoriatics related to methotrexate therapy. 2. Findings before and after methotexate therapy in 88 patients. A blind study. Acta Pathol Microbiol Scand 1976; 84: 262-70.
29. Zachariae H, Grunnet E, Sogaard H,. Liver biopsy in methotrexate-treated psoriatics-a re-evalution. Acta Derm Venereol 1975; 55: 291-6.
30. Ashton RE, Millward-Sadler GH, White JE,. Complications in methotrexate treatment of psoriasis with particular reference to liver fibrosis. J Invest Dermatol 1982; 79: 229-32.
31. Roenigk HH Jr, Auerbach R, Maibach HI, et al,. Methotrexate guidelines-revised. J Am Acad Dermatol 1982; 6: 145-55.
32. Brunt EM, Janney CG, Di Bisceglie AM, et al,. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.